RecruitingNCT03720197

Registry of Patients Living With Type 1 Diabetes

Registry of Individuals With Type 1 Diabetes Living in Canada: The BETTER Registry

Sponsor

Institut de Recherches Cliniques de Montreal

Enrollment

6,000 participants

Start Date

Feb 20, 2019

Study Type

OBSERVATIONAL

Conditions

Type 1 Diabetes Mellitus

Summary

A registry of individuals with type 1 diabetes open to all patients with type 1 diabetes living in Canada will be established. The objective of this registry will be to measure the frequency and the severity of episodes of hypoglycemia. Participants will be invited to answer questionnaires about the frequency of their hypoglycemic episodes, their fear about hypoglycemia, their symptoms of hypoglycemia, the factors in cause (insulin therapy, nutrition, exercise, etc.), etc. Participation to the registry is divided in 3 phases. The first phase is mandatory for all participants. Phases 2 and 3 are optional.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a patient registry collecting information from Canadians living with type 1 diabetes (an autoimmune condition where the body does not produce insulin) to build a national database that will help researchers better understand the disease, treatment outcomes, and quality of life over time. **You may be eligible if...** - You have been diagnosed with type 1 diabetes - You currently live in Canada **You may NOT be eligible if...** - You have type 2 diabetes (where the body doesn't use insulin properly) - You have gestational diabetes (diabetes that develops during pregnancy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROnline questionnaire - Phase 1

Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.

OTHEROnline questionnaire - Phase 2

Characterize the causes, experience and consequences of hypoglycemia.

OTHEROnline questionnaire - Phase 3

Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.

OTHERFood questionnaire

24-hour food recall questionnaire

OTHERPedometer

Participants will wear a podometer for 14 consecutives days

OTHERWaist circumference

Participants will be asked to measure their waist circumference

OTHERBlood and urine tests

Participants will be invited to send us their latests blood and urine test results.

OTHERList of medications

Participants will be invited to send us their list of medications

OTHERContinuous glucose monitor

Participants will be invited to send us the latest report of their continuous glucose monitor

Locations(7)

Alberta Diabetes Institute

Edmonton, Alberta, Canada

Institut de recherches cliniques de Montréal

Montreal, Quebec, Canada

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Centre Hospitalier Universitaire Sainte-Justine

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Centre Hospitalier Universitaire de Québec-Université Laval

Québec, Quebec, Canada

Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03720197

Related Trials

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT0678330928 locations

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

NCT0691935410 locations

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068141 locations

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

NCT075489961 location

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT0722432110 locations